A 1-year per-patient cost of therapy administration analysis of mosunetuzumab and tisagenlecleucel in relapsed or refractory follicular lymphoma patients receiving two or more lines of systemic therapy

A 1-year per-patient cost of therapy administration analysis of mosunetuzumab and tisagenlecleucel in relapsed or refractory follicular lymphoma patients receiving two or more lines of systemic therapy

Objective: A per-patient cost of therapy administration model was developed to estimate the cost of mosunetuzumab vs. tisagenlecleucel in patients with relapsing or refractory follicular lymphoma (R/R FL) receiving two or more lines of systemic therapy (3L+) from both the Italian hospital and societ...

Full description

Saved in:
Bibliographic Details
Main Authors: Marco Bellone, Alice Sabinot, Alessandro D’Arpino, Emanuela Omodeo Salè, Daniela Ghislieri, Lorenzo Pradelli
Format: Article
Language:English
Published: AboutScience Srl 2024-12-01
Series:Global & Regional Health Technology Assessment
Subjects:
Economic evaluation
Healthcare costs
Micro-costing
Oncology
Online Access:https://journals.aboutscience.eu/index.php/grhta/article/view/3170
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://journals.aboutscience.eu/index.php/grhta/article/view/3170

Similar Items